{
    "clinical_study": {
        "@rank": "115895", 
        "arm_group": [
            {
                "arm_group_label": "LDE225+Warfarin", 
                "arm_group_type": "Experimental", 
                "description": "At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group."
            }, 
            {
                "arm_group_label": "LDE225+Bupropion", 
                "arm_group_type": "Experimental", 
                "description": "At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi center, open-label study to study the drug-drug interaction of LDE225 on the\n      PK of warfarin and bupropion in patients with advanced solid tumors. Subjects will receive\n      800mg daily of LDE225 and two separate doses of either bupropion or warfarin."
        }, 
        "brief_title": "Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults\n\n          -  Patients with cytopathologically or histopathologically confirmed diagnosis of an\n             advanced solid tumor which has progressed despite standard therapy, or for which no\n             standard therapy exists.\n\n          -  Protocol-defined renal , liver and bone marrow function\n\n        Exclusion Criteria:\n\n          -  CNS (Central Nervous System) tumors as well as history of brain metastases\n\n          -  Systemic anticancer treatment (including biologic therapy/antibodies) within 2 weeks\n             before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and\n             monoclonal antibodies).\n\n          -  Radiation therapy within 4 weeks before first dose\n\n          -  Investigational agents within 4 weeks  before start of study therapy\n\n          -  Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related\n             compounds\n\n          -  Patients with a history of/or active bleeding disorders\n\n          -  Patients receiving treatment with vitamin K, Coumadin or other agents containing\n             warfarin and heparin.  Heparin flush to maintain patency of a central venous access\n             device is allowed.\n\n          -  Patients receiving treatment with bupropion.\n\n          -  Patients who have neuromuscular disorders that are associated with elevated CK\n             (Creatine phosphokinase)  (e.g., inflammatory myopathies, muscular dystrophy,\n             amyotrophic lateral sclerosis, spinal muscular atrophy).\n\n          -  Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is\n             not mandatory for study entry)\n\n          -  Patients currently receiving systemic corticosteroids Other protocol-defined\n             inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769768", 
            "org_study_id": "CLDE225A2112"
        }, 
        "intervention": [
            {
                "arm_group_label": "LDE225+Warfarin", 
                "description": "LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.", 
                "intervention_name": "LDE225", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LDE225+Warfarin", 
                "description": "15 mg single dose of warfarin (oral tablet) will be given to patients.", 
                "intervention_name": "Wafarin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LDE225+Bupropion", 
                "description": "bupropion 75 mg single dose (oral tablet, from an immediate release formulation) will be given to patients", 
                "intervention_name": "Bupropion", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Warfarin", 
                "Bupropion"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Adults, Hh (Hedgehog) pathway inhibitor, LDE225, Warfarin, Bupropion, advanced solid tumor, drug-drug interaction, pharmacokinetic", 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "720-848-0664"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Karl Lewis", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "913-588-5095"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "Univ. of Kansas Medical Center CBYM338B2203"
                }, 
                "investigator": {
                    "last_name": "Raymond Perez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "617-632-4936"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Geoffrey Shapiro", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "313-576-8749"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia M. LoRusso", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "603-650-4828"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr"
                }, 
                "investigator": {
                    "last_name": "Lionel Lewis", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Hackensack University Medical Center Dept.of HackensackUniv.MedCtr."
                }, 
                "investigator": {
                    "last_name": "Martin E Gutierrez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "215-728-5534"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Anthony Olszanski", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "215-796-5159"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania--Abramson Cancer Center Abramson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ravi Amaravadi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "843-792-4271"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina Dept.of Neurosciences/MS Ctr."
                }, 
                "investigator": {
                    "last_name": "Carolyn Britten", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "210-616-5069"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Therapy & Research Center"
                }, 
                "investigator": {
                    "last_name": "John Sarantopoulos", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "801-581-5062"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "University of Utah / Huntsman Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Sunil Sharma", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration", 
                "measure": "Pharmacokinetics (PK) parameter AUClast for S- and R-warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Pharmacokinetics bupropion : Maximum observed plasma concentration after drug administration", 
                "measure": "PK parameter AUClast for bupropion", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Pharmacokinetics of bupropion : Maximum observed plasma concentration after drug administration", 
                "measure": "PK parameter AUCinf for bupropion", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Pharmacokinetics of warfarin and bupropion : Maximum observed plasma concentration after drug administration", 
                "measure": "PK parameter AUCinf for S- and R-warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration", 
                "measure": "PK parameter Cmax for S- and R-warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Pharmacokinetics of Bupropion : Maximum observed plasma concentration after drug administration", 
                "measure": "PK parameters Cmax for bupropion", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769768"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "INR parameter (International Normalized Ratio) will be assessed to evaluate the pharmacodynamic effect of warfarin.", 
                "measure": "effects of LDE225 on the pharmacodynamic activity of warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "safety laboratory parameters, adverse event reports, changes in vital signs, changes in physical examination parameters", 
                "measure": "safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "28 days cycles"
            }, 
            {
                "description": "CT or MRI imaging parameters to determine the objective response rate according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)", 
                "measure": "evaluate the preliminary evidence of anti-tumor activity of LDE225 in patients with advanced solid tumors", 
                "safety_issue": "No", 
                "time_frame": "every other cycle"
            }, 
            {
                "description": "ECGs will be performed to determine the effect of LDE on the cardiac function.", 
                "measure": "assess the effect of LDE225 treatment on cardiac function", 
                "safety_issue": "Yes", 
                "time_frame": "screening, cycle 4 and EOT"
            }, 
            {
                "description": "PT (Prothrombin time) parameter will be assessed to evaluate the pharmacodynamic effect of warfarin.", 
                "measure": "effects of LDE225 on the pharmacodynamic activity of warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "safety laboratory parameters", 
                "measure": "safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "28 days cycles"
            }, 
            {
                "description": "adverse event reports", 
                "measure": "safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "28 days cycles"
            }, 
            {
                "description": "changes in vital signs", 
                "measure": "safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin", 
                "safety_issue": "Yes", 
                "time_frame": "28 days cycles"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}